Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Recruiting Phase 3 Interventional

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

NCT07071519
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
12
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional Results available

An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease

NCT01009281
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
AIN457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Bristol, Connecticut • Great Neck, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 21, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

NCT05666960
View directory record Official record
Conditions
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic, Ulcerative Colitis
Interventions
R-3750
Drug
Lead sponsor
Rise Therapeutics LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Valencia, California • Miami, Florida • Plantation, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Recruiting Not applicable Interventional

Impact of Prebiotics in Ulcerative Colitis

NCT06495658
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Prebiotic
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Recruiting Not applicable Interventional

STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission

NCT06693310
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
de-escalation or discontinuation of therapy, continuation of current therapy
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Not applicable Interventional Results available

Irritable Bowel Syndrome Hypnotherapy

NCT01248013
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
gut focused hypnotherapy
Behavioral
Lead sponsor
Mind-Body Digestive Center
Other
Eligibility
20 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease

NCT00790933
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
31
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 21, 2026, 5:36 AM EDT
Completed No phase listed Observational

Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease

NCT00790543
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
5 Days to 16 Years
Enrollment
1,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
25
States / cities
Los Angeles, California • San Francisco, California • Hartford, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 21, 2026, 5:36 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

NCT05731128
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

NCT02589665
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Chula Vista, California • La Jolla, California • Rialto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis

NCT00048347
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AVONEX
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

NCT00446433
View directory record Official record
Conditions
Crohn's Disease
Interventions
CC-5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
12 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Tucson, Arizona • Anaheim, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 21, 2026, 5:36 AM EDT
Recruiting No phase listed Observational

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

NCT07237516
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease (CD), Indeterminate Colitis, Inflammatory Bowel Disease (IBD)
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
New Haven, Connecticut • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain

NCT06381921
View directory record Official record
Conditions
Abdominal Pain
Interventions
IBS-PPSM intervention
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Early Serum Infliximab Levels in Severe Ulcerative Colitis.

NCT01971814
View directory record Official record
Conditions
Ulcerative Colitis (UC), Inflammatory Bowel Disease
Interventions
Infliximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

NCT01327300
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mesalamine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

NCT00771667
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo (IP), Ustekinumab 1mg/kg (IP), Ustekinumab 3 mg/kg (IP), Ustekinumab 6 mg/kg (IP), Placebo IV - Responder - Placebo SC (MP), Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP), Ustekinumab IV - Responder - Placebo SC (MP), Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP), Ustekinumab IV - Nonresponder - Placebo SC (MP), Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
88
States / cities
Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Not applicable Interventional Results available

A Dietary Intervention Study on the Microbiome in Crohn's Disease Patients

NCT04065048
View directory record Official record
Conditions
Crohn Disease
Interventions
Soy based diet, Non-soy based diet
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Completed No phase listed Observational

OPERA Database - Crohn's Protocol

NCT01720368
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

NCT00628433
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, HE3286
Drug
Lead sponsor
Harbor Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Tucson, Arizona • Anaheim, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

NCT01532648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Budesonide MMX®, Placebo, 5-ASA
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Anaheim, California • Lakewood, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 21, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

NCT02559817
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
46
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Oct 21, 2026, 5:36 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People

NCT01162889
View directory record Official record
Conditions
Healthy
Interventions
Placebo SC Injection, ATR-107 (PF-05230900) SC Injection, ATR-107 (PF-05230900) IV Infusion, Placebo IV Infusion
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Not applicable Interventional

Analysis of Biologic Signatures in Crohn's Patients Undergoing Surgery

NCT06146335
View directory record Official record
Conditions
Crohn Disease
Interventions
Kono-S anastomosis (KSa), Side-to-side anastomosis (SSa)
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 21, 2026, 5:36 AM EDT